Shun Lu

58PUBLICATIONS
237CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsGene and molecular therapyMedical biotechnology diagnostics (incl. biosensors)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (58)

|Sep 09, 2026
Osimertinib After Definitive Chemoradiotherapy in Unresectable Stage III EGFR-Mutated NSCLC: Subsequent Treatments and PPO From the Phase III LAURA Study.

|Jun 26, 2026
Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

|Jun 02, 2026
MYBL2 impedes cisplatin sensitivity through suppressing GSDME-mediated pyroptosis in lung adenocarcinoma.

|May 25, 2026
TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer.

|Mar 10, 2026
A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice.

Haiyan Zhou, Ruiming Sun, Xiaoqun Nie

|Jun 18, 2025
OX40-heparan sulfate binding facilitates CAR T cell penetration into solid tumors in mice.

Huihui Zhang, Runbo Zhong, Wanting Wang

Pageof 10

Frequent Collaborators

5 joint publications

Nicolas Girard

5 joint publications

James Chih-Hsin Yang

4 joint publications

Xiaokuan Zhu

3 joint publications

Byoung Chul Cho